Main Session: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

What are the mechanisms of action for novel extended adjuvant therapies?

G. Thomas Budd, MD

G. Thomas Budd, MD, on advances in extended adjuvant HER2+ early breast cancer.

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here